184 results on '"Matsushita, Maiko"'
Search Results
2. Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
3. Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy
4. Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
5. GTN057 , a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase
6. This title is unavailable for guests, please login to see more information.
7. This title is unavailable for guests, please login to see more information.
8. Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
9. Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
10. Codon 72 polymorphism of TP53 gene is a novel prognostic marker for therapy in multiple myeloma
11. This title is unavailable for guests, please login to see more information.
12. A phenylphthalimide derivative, TC11, induces apoptosis by degrading MCL1 in multiple myeloma cells
13. Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph+ B cells but not bone marrow stem/progenitors
14. Characteristics of a Novel Target Antigen against Myeloma Cells for Immunotherapy
15. Abstract B73: A novel candidate for immunologic target in treatment of multiple myeloma
16. Possible involvement of allogeneic antigens recognised by donor-derived CD4+ cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy
17. This title is unavailable for guests, please login to see more information.
18. This title is unavailable for guests, please login to see more information.
19. A novel derivative (GTN024) from a natural product, komaroviquinone, induced the apoptosis of high-risk myeloma cells via reactive oxygen production and ER stress
20. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia
21. Can Rare Cancer Drugs Expect Sales in Japan?: A Prescription Pattern Analysis of Drugs for Chronic Myelogenous Leukemia and Neuroendocrine Tumor
22. A Study on the Description of Anticancer Drug Combination Therapy in the Package Insert in Japan
23. Relationships between approved combination therapies and clinical data packages in anti-cancer drugs in Japan
24. Japan oncology market overview: Current and future perspectives
25. A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myeloma cells via G2/M cell-cycle arrest
26. Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma
27. This title is unavailable for guests, please login to see more information.
28. Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph+ B cells but not bone marrow stem/progenitors.
29. Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy
30. Can Rare Cancer Drugs Expect Sales in Japan?: A Prescription Pattern Analysis of Drugs for Chronic Myelogenous Leukemia and Neuroendocrine Tumor
31. Abstract B177: Analysis of immunogenic cell death (ICD) induced in multiple myeloma cells
32. Elucidation of the IMiDs-Resistant Mechanism and Development of the Overcoming Drugs Inducing CRBN Independent G2/M Cell Cycle Arrest in Myeloma Cells
33. Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma
34. Abstract A82: Evaluation of novel immune target in hematologic malignancies
35. 1,25-Dihydroxyvitamin D3 Induces Differentiation of a Retinoic Acid–Resistant Acute Promyelocytic Leukemia Cell Line (UF-1) Associated With Expression of p21WAF1/CIP1 and p27KIP1
36. Supplemental Material, TIRS-17-0136_rev_Supplemental_Table_1_20171104 - Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
37. Abstract 5121: PEG(E)-TC11, a novel polyethylene glycol-linked phthalimide derivative, inhibited high-risk MM cell growthin vivoandin vitrovia cell cycle G2/M arrest in a CRBN-independent manner
38. This title is unavailable for guests, please login to see more information.
39. MO1-11-2 - Relationships between approved combination therapies and clinical data packages in anti-cancer drugs in Japan
40. An Empirical Study of the Prescription Pattern of Drugs for Hematological Malignancies in Japan from 2010–2014
41. This title is unavailable for guests, please login to see more information.
42. Komaroviquinone-Derivatives, Revealed Anti-Tumor Effect on High-Risk Multiple Myeloma Cells In Vitro as Well as In Vivo
43. 10 Years History of Cost-Effectiveness for 209 Newly Diagnosed Multiple Myeloma Patients at a Single-Institute in Japan
44. Unique changes in prescription patterns of drugs for hematological malignancies in Japan.
45. Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies
46. Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs
47. Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
48. A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon
49. A Novel Phthalimide Derivative, TC11, Has Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts
50. Quantitative Analysis of PRAME for Detection of Minimal Residual Disease in Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.